Chinese PLA General Hospital

Clinical Trial Update – CRISPR-Engineered Dual...
Jan. 20, 2021

This week’s gene-editing clinical trial update looks at a universal dual specificity CD19 and CD20/CD22 CAR-T cell immunotherapy that is being...

Chinese PLA General Hospital

B-Cell Non-hodgkin Lymphoma, NHL, (NCT06014073)
Sponsors:
Chinese PLA General Hospital
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
B-Cell Non-hodgkin Lymphoma, NHL, (NCT05631912)
Sponsors:
Chinese PLA General Hospital
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumor, Adult, (NCT04976218)
Sponsors:
Chinese PLA General Hospital
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-Cell Malignancies, (NCT03398967)
Sponsors:
Chinese PLA General Hospital
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-Cell Malignancies, (NCT03166878)
Sponsors:
Chinese PLA General Hospital
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumor, Adult, (NCT03747965)
Sponsors:
Chinese PLA General Hospital
Indicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumor Adult, (NCT03545815)
Sponsors:
Chinese PLA General Hospital
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine